Sutro Biopharma, Inc. (NASDAQ:STRO – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 29th, there was short interest totaling 751,365 shares, a decline of 37.0% from the May 14th total of 1,193,156 shares. Based on an average daily volume of 434,201 shares, the short-interest ratio is presently 1.7 days. Currently, 4.8% of the company’s shares are short sold.
Sutro Biopharma Stock Performance
STRO traded up $0.94 during trading on Wednesday, hitting $29.11. 187,036 shares of the stock were exchanged, compared to its average volume of 211,795. The firm has a 50 day simple moving average of $31.21 and a 200 day simple moving average of $21.26. The firm has a market cap of $482.27 million, a price-to-earnings ratio of -2.64 and a beta of 1.54. Sutro Biopharma has a 1 year low of $6.74 and a 1 year high of $43.85.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.20). The business had revenue of $14.52 million during the quarter, compared to the consensus estimate of $8.89 million. As a group, equities analysts anticipate that Sutro Biopharma will post -9.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on Sutro Biopharma
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP bought a new position in shares of Sutro Biopharma during the third quarter valued at approximately $152,000. Spruce Street Capital LP bought a new position in shares of Sutro Biopharma during the fourth quarter valued at approximately $875,000. Perceptive Advisors LLC bought a new position in shares of Sutro Biopharma during the first quarter valued at approximately $17,818,000. Bridgeway Capital Management LLC boosted its stake in shares of Sutro Biopharma by 232.6% during the third quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Sutro Biopharma by 137.8% during the first quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after purchasing an additional 53,390 shares in the last quarter. 96.99% of the stock is currently owned by hedge funds and other institutional investors.
About Sutro Biopharma
Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.
Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.
Featured Stories
- Five stocks we like better than Sutro Biopharma
- 3 Stocks to Watch If the Strait of Hormuz Reopens
- Draining the Tank: Big Oil Runs on Fumes
- Microsoft’s Xbox Problem Is Bigger Than a Console War
- Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
